We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety, Efficacy and Persistence of Advanced Therapies in Inflammatory Bowel Disease: Results from ORIGINS. A Retrospective Observational Study.
- Authors
Mateescu, Radu Bogdan; Gheorghe, Cristian; Trifan, Anca Victorita; Saftoiu, Adrian; Seicean, Andrada; Diculescu, Mihai Mircea; Banciu, Christian; Gheorghe, Liliana Simona; Busuioc, Bogdan; Goldis, Adrian; Dobru, Daniela; Fratila, Ovidiu; Eugen, Dumitru; Bataga, Simona; Constantinescu, Gabriel; Gheonea, Dan; Tantau, Alina; Jinga, Mariana; Brisc, Ciprian; Prelipcean, Cristina Cijevschi
- Abstract
Background & Aims: Real-world assessments of efficacy and safety of advanced therapies used for inflammatory bowel disease (IBD) patients are limited. We aimed to report safety, efficacy and treatment persistence of new molecules (infliximab, adalimumab, vedolizumab, tofacitinib, ustekinumab) in a retrospective multicentric national Romanian analysis. Methods: We conducted a nationwide, retrospective observational multicentric study. Data were collected retrospectively from electronic and paper files. Patients who started on one of the five investigated molecules during December 2019-December 2021 were included. The main outcome measures were clinical remission, endoscopic healing, persistence on treatment and safety data. Results: A total of 678 adult patients from 24 Romanian IBD centers with a diagnosis of ulcerative colitis or Crohn's disease were included. Participants had previously failure to one (268, 39.5%), two (108, 15%) or more treatment lines and only 38% (259) were biologic naïve. In the 24 months study period, most patients were started on vedolizumab (192, 28%), followed by adalimumab, infliximab, ustekinumab and tofacitinib. In biologic-naïve patients, most physicians (72%) preferred anti-TNF treatment as first line biologic (93 patients started on infliximab, 92 on adalimumab), followed by vedolizumab, ustekinumab and tofacitinib. During follow-up, 71% (470, p=0.05) of patients achieved clinical remission and 36% (134, p=0.03) achieved mucosal healing. The 6 months milestone for persistence was reached in 78% (530) of cases. Almost half of patients (47%, 316 patients) persisted on their current treatment for over 12 months. Overall, an adverse reaction was reported for 67 (10.4%) patients, with no lethal events. Conclusions: Population of biologic-experienced IBD patients in Romania is increasing and is becoming more difficult to achieve long-term disease control. Discontinuation rates for advanced therapies are high.
- Subjects
ROMANIA; INFLAMMATORY bowel diseases; CROHN'S disease; ULCERATIVE colitis; ELECTRONIC paper; DISEASE remission
- Publication
Journal of Gastrointestinal & Liver Diseases, 2023, Vol 32, Issue 4, p444
- ISSN
1841-8724
- Publication type
Article
- DOI
10.15403/jgld-5128